Lymphoma
Showing NaN - NaN of 246
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Lymphoma, Nonneoplastic Condition Trial in United States (bleomycin sulfate, filgrastim, ABVD regimen)
Completed
- Lymphoma
- Nonneoplastic Condition
- bleomycin sulfate
- +11 more
-
Tucson, Arizona
- +422 more
Aug 16, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +7 more
- Busulfan
- +11 more
-
Duarte, California
- +26 more
Aug 11, 2022
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))
Recruiting
- Locally Advanced Solid Tumors
- +3 more
- Oral repotrectinib (TPX-0005)
-
Los Angeles, California
- +27 more
Aug 9, 2022
Collecting and Storing Tissue From Young Patients With Cancer
Recruiting
- Acute Lymphoblastic Leukemia
- +13 more
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis
-
Birmingham, Alabama
- +68 more
Aug 4, 2022
Leukemia, Myelodysplastic Syndrome, Lymphoma Trial in New York (CliniMACS Fractionation system (Arm A), CliniMACS Fractionation
Completed
- Leukemia
- +2 more
- CliniMACS Fractionation system (Arm A)
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 12, 2022
Hematopoietic and Lymphoid System Tumor, Leukemia, Lymphoma Trial in Canada, United States (procedure, biological, other)
Active, not recruiting
- Hematopoietic and Lymphoid System Neoplasm
- +3 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +3 more
-
Birmingham, Alabama
- +42 more
Jul 20, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma Trial in United States (biological, drug, procedure)
Active, not recruiting
- Acute Lymphoblastic Leukemia
- +3 more
- BPX-501 dose 1
- +5 more
-
Atlanta, Georgia
- +7 more
Jul 10, 2022
Breast Cancer, Head Neck Cancer, Squamous Cell Carcinoma Trial in Canada, United States (INT230-6, anti-PD-1 antibody,
Active, not recruiting
- Breast Cancer
- +10 more
- INT230-6
- +2 more
-
Los Angeles, California
- +7 more
Jun 21, 2022
Lymphoma, Multiple Myeloma Trial in Worldwide (Lenalidomide, Dexamethasone, Dexamethasone (Oral))
Completed
- Lymphoma
- Multiple Myeloma
- Lenalidomide
- +4 more
-
Muscle Shoals, Alabama
- +215 more
May 5, 2022
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma Trial in New York (Isatuximab, Standard Procedures)
Recruiting
- Lymphoma
- +3 more
- Isatuximab
- Standard Procedures
-
New York, New YorkColumbia University
Apr 27, 2022
GI Cancer, Lymphoma, GU Cancer Trial in New York (Self-Efficacy Assessment, UCLA Geriatrics Attitudes Scale, Course Evaluations)
Active, not recruiting
- GI Cancer
- +3 more
- Self-Efficacy Assessment
- +5 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 16, 2022
Leukemia, Lymphoma, Lymphoma, B-Cell Trial in New York (CAR T-Cell Infusion)
Withdrawn
- Leukemia
- +2 more
- CAR T-Cell Infusion
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 4, 2022
Lymphoma Trial in United States (rituximab, Bendamustin, bortezomib)
Active, not recruiting
- Lymphoma
- rituximab
- +3 more
-
Greenbrae, California
- +226 more
Mar 7, 2022
Longitudinal Sexual and Reproductive Health Study of Breast
Recruiting
- Breast Cancer
- +2 more
- surveys
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Mar 1, 2022
Mantle Cell Lymphoma, Lymphoma Trial in United States (BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax))
Active, not recruiting
- Mantle Cell Lymphoma
- Lymphoma
- BR-I (bendamustine, rituximab, ibrutinib)
- VEN (Venetoclax)
-
Basking Ridge, New Jersey
- +6 more
Feb 3, 2022
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (Durvalumab, Lenalidomide, Rituximab)
Active, not recruiting
- Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Durvalumab
- +4 more
-
Gilbert, Arizona
- +53 more
Jan 25, 2022